Syngenta acquires genetic repository from Novartis to boost biologic crop protection
Portfolio Pulse from
Syngenta has acquired a repository of natural compounds and genetic strains from Novartis to enhance its biologic crop protection development.
February 26, 2025 | 10:00 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Novartis has sold a repository of natural compounds and genetic strains to Syngenta, which may impact its focus on core pharmaceutical operations.
The sale of the genetic repository to Syngenta suggests Novartis is divesting non-core assets, which could streamline its focus on pharmaceuticals. However, the direct financial impact on Novartis is not detailed, leading to a neutral short-term price impact.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 70